Table 5 Incidence rate ratio (IRR) of TBD in IMID patients being treated with the different classes of DMARDs
DMARD | Incidence/100,000 py | IRR | p-value |
|---|---|---|---|
tsDMARDs | 234 | Comparator | Comparator |
csDMARDs | 392 | 1.6748 | < 0.00001 |
All TNFi | 844 | 3.6056 | < 0.00001 |
Etanercept | 390 | 1.6672 | < 0.0001 |
Adalimumab | 948 | 4.0488 | < 0.0001 |
Infliximab | 981 | 4.1910 | < 0.0001 |
Certolizumab pegol | 193 | 0.8248 | 0.0474 |
Golimumab | 532 | 2.2752 | < 0.0001 |
Non-TNFi bDMARDs | 379 | 1.6198 | < 0.0001 |
Tocilizumab | 320 | 1.3690 | 0.0003 |
Rituximab | 720 | 3.0783 | < 0.0001 |
Abatacept | 351 | 1.4977 | < 0.0001 |